Description

Congestive Heart Failure Treatment market: Congestive heart failure is a chronic and progressive condition that affects the pumping capacity of heart muscles and also referred as “heart failure”. Congestive heart failure can refer to the stage in which fluid builds up around the heart and causes it to pump inefficiently. Ventricles pump blood to your body’s organs and tissues, and the atria receive blood from your body as it circulates back from the rest of your body. Congestive heart failure develops when ventricles unable to pump sufficient volume of blood to the body. Eventually, blood and other fluids can back up inside your lungs, liver, abdomen, and lower body. There are two types of congestive heart failure, they are systolic heart failure and diastolic heart failure.

 

Increase in prevalence of cardiovascular diseases across regions is one the major factors expected to drive the revenue growth of congestive heart failure treatment globally. Lifestyle related factors are expected to add to growing disease incidence of CVDs. In addition growing number of obese patients are expected to bolster the congestive heart failure treatment market. ast track approvals of drugs in developed countries will propel sales revenues for the companies. Huge treatment demand for congestive heart failure is expected to boost the treatment market developing. However, the availability of the generic drugs and lack of end stage pipeline drugs and therapies for congestive heart failure treatment is about to hinder the market.

 

Congestive Heart Failure Treatment market is segmented on the basis of the drug class, route of administration, and distribution channel

 

Based on drug class, global market is segmented as

  • Beta Blockers
  • ACE Inhibitors
  • Angiotensin Receptor Blockers
  • Diuretics
  • Inotropic Agents
  • Aldosterone Antagonist
  • Calcium Channel Blockers
  • Others

 

Based on route of administration, global market is segmented as

 

Based on distribution channel, global market is segmented as

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

 

Congestive heart failure treatment market is expected to show significant growth in demand over the forecast period owing to rising incidences of cardiovascular diseases. Congestive heart failure is one of the most common medical conditions that is responsible for the death of people globally. According to WHO, around 6.5 million of people are diagnosed with congestive heart failure every year and around 2% of global population are hospitalized due to congestive heart failure. In July, 2015, Novartis launched novel combination drug Entresto (LCZ-696) a novel branded CHF drug. The prescription of mineralocorticoid receptor antagonists (MRAs), such as spironolactone, due to their efficiency in heart failure treatment is expected to increase the Congestive heart failure (CHF) treatment markets during the forecast period.  Many generic manufacturers foray into the congestive heart failure treatment market due to patent expirations of CHF innovators drugs. The presence generics expected to hinder the market revenue and may hamper the uptake of new and expected novel drugs.

 

Geographically global market has been segmented into following regions viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America and European markets are significantly having high growth potential for congestive heart failure treatment due to the increase in incidences of heart failures in these regions. According to American Heart Association, Heart Disease and Stroke Statistics 2017, congestive heart failure occupies 8.5% of heart diseases in US. merging markets like Asia Pacific and Latin America are set to witness significant growth in this industry due to change in demographics, healthcare reforms, healthcare expenditure, and an increase in treatment for congestive heart failure conditions.

 

Some of the players in the global congestive heart failure (CHF) treatment market are AstraZeneca plc. (UK), Bristol-Myers Squibb Co. (U.S), GlaxoSmithKline plc (GSK) (UK), Merck & Co. Inc. (U.S), Mylan Inc. (U.S), Novartis AG (Switzerland), Pfizer Inc. (U.S), Sanofi (France), and Valeant Pharmaceuticals International Inc. (Canada)

  • In July 2015, U.S. Food and Drug Administration (FDA) approved Novartis, Entresto (sacubitril/valsartan) tablets, previously known as LCZ696, to treat heart failure patients with reduced ejection fraction

 

  • In April 2015, Amgen received U.S. FDA approval for its Corlanor (ivabradine) to treat of heart failure conditions

 

Report Outline:

 

  • The report provides granular level information about the market size, regional market share and forecast from 2017-2023
  • The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
  • The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
  • The report tracks recent innovations, key developments and startup’s details that are working in the industry
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario


Location

GEOGRAPHY

PBI Location Map

1. Executive Summary
2. Global Congestive Heart Failure Treatment Market Introduction
2.1. Global Congestive Heart Failure Treatment Market – Taxonomy
2.2. Global Congestive Heart Failure Treatment Market –Definitions
2.2.1. Drug Class
2.2.2. Route of Administration
3. Global Congestive Heart Failure Treatment Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Congestive Heart Failure Treatment Market Dynamic Factors – Impact Analysis
4. Global Congestive Heart Failure Treatment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024
4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Congestive Heart Failure Treatment Market, By Drug Class, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
5.1. Beta Blockers
5.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. ACE Inhibitors
5.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Angiotensin Receptor Blockers
5.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Diuretics
5.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Inotropic Agents
5.5.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
5.6. Aldosterone Antagonist
5.6.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.6.3. Market Opportunity Analysis
5.7. Calcium Channel Blockers
5.7.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
5.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.7.3. Market Opportunity Analysis
5.8. Others
5.8.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
5.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.8.3. Market Opportunity Analysis
6. Global Congestive Heart Failure Treatment Market, By Route of Administration, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
6.1. Oral
6.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. parenteral
6.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
7. Global Congestive Heart Failure Treatment Market, By Distribution Channel, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
7.1. Hospital Pharmacies
7.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Retail Pharmacies
7.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Online Pharmacies
7.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
8. Global Congestive Heart Failure Treatment Market Forecast, By Region, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
8.1. North America
8.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
8.6. Global Congestive Heart Failure Treatment Market – Opportunity Analysis Index, By Drug Class, By Route of Administration, By Distribution Channel, and Region, 2018 – 2024
9. North America Congestive Heart Failure Treatment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
9.1. Drug Class Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1. Beta Blockers
9.1.2. ACE Inhibitors
9.1.3. Angiotensin Receptor Blockers
9.1.4. Diuretics
9.1.5. Inotropic Agents
9.1.6. Aldosterone Antagonist
9.1.7. Calcium Channel Blockers
9.1.8. Others
9.2. Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.2.1. Oral
9.2.2. Parenteral
9.3. Distribution Channel Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.4. Country Analysis 2016 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.4.1. US
9.4.2. Canada
9.5. North America Congestive Heart Failure Treatment Market – Opportunity Analysis Index, By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2018 – 2024
9.6. North America Congestive Heart Failure Treatment Market Dynamics – Trends
10. Europe Congestive Heart Failure Treatment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
10.1. Drug Class Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Beta Blockers
10.1.2. ACE Inhibitors
10.1.3. Angiotensin Receptor Blockers
10.1.4. Diuretics
10.1.5. Inotropic Agents
10.1.6. Aldosterone Antagonist
10.1.7. Calcium Channel Blockers
10.1.8. Others
10.2. Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.2.1. Oral
10.2.2. Parenteral
10.3. Distribution Channel Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Online Pharmacies
10.4. Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.4.1. Germany
10.4.2. UK
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Russia
10.4.7. Poland
10.4.8. Rest of Europe
10.5. Europe Congestive Heart Failure Treatment Market – Opportunity Analysis Index, By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2018 – 2024
10.6. Europe Congestive Heart Failure Treatment Market Dynamics – Trends
11. Asia-Pacific Congestive Heart Failure Treatment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
11.1. Drug Class Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Beta Blockers
11.1.2. ACE Inhibitors
11.1.3. Angiotensin Receptor Blockers
11.1.4. Diuretics
11.1.5. Inotropic Agents
11.1.6. Aldosterone Antagonist
11.1.7. Calcium Channel Blockers
11.1.8. Others
11.2. Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.2.1. Oral
11.2.2. Parenteral
11.3. Distribution Channel Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.3.1. Hospital Pharmacies
11.3.2. Retail Pharmacies
11.3.3. Online Pharmacies
11.4. Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.4.1. Japan
11.4.2. China
11.4.3. India
11.4.4. ASEAN
11.4.5. Australia & New Zealand
11.4.6. Rest of Asia-Pacific
11.5. Asia-Pacific Congestive Heart Failure Treatment Market – Opportunity Analysis Index, By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2018 – 2024
11.6. Asia-Pacific Congestive Heart Failure Treatment Market Dynamics – Trends
12. Latin America Congestive Heart Failure Treatment Market Analysis, 2012 – 2012 – 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
12.1. Drug Class Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Beta Blockers
12.1.2. ACE Inhibitors
12.1.3. Angiotensin Receptor Blockers
12.1.4. Diuretics
12.1.5. Inotropic Agents
12.1.6. Aldosterone Antagonist
12.1.7. Calcium Channel Blockers
12.1.8. Others
12.2. Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.2.1. Oral
12.2.2. Parenteral
12.3. Distribution Channel Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.3.1. Hospital Pharmacies
12.3.2. Retail Pharmacies
12.3.3. Online Pharmacies
12.4. Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Argentina
12.4.4. Venezuela
12.4.5. Rest of Latin America
12.5. Latin America Congestive Heart Failure Treatment Market – Opportunity Analysis Index, By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2018 – 2024
12.6. Latin America Congestive Heart Failure Treatment Market Dynamics – Trends
13. Middle East and Africa Congestive Heart Failure Treatment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
13.1. Drug Class Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1. Beta Blockers
13.1.2. ACE Inhibitors
13.1.3. Angiotensin Receptor Blockers
13.1.4. Diuretics
13.1.5. Inotropic Agents
13.1.6. Aldosterone Antagonist
13.1.7. Calcium Channel Blockers
13.1.8. Others
13.2. Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.2.1. Oral
13.2.2. Parenteral
13.3. Distribution Channel Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.3.1. Hospital Pharmacies
13.3.2. Retail Pharmacies
13.3.3. Online Pharmacies
13.4. Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
13.4.1. Gulf Cooperation Council (GCC) Countries
13.4.2. Israel
13.4.3. South Africa
13.4.4. Rest of MEA
13.5. MEA Congestive Heart Failure Treatment Market – Opportunity Analysis Index, By Drug Class, By Distribution Channel, By Route of Administration, and Country, 2018 – 2024
13.6. MEA Congestive Heart Failure Treatment Market Dynamics – Trends
14. Competition Landscape
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. AstraZeneca plc. (UK)
14.2.2. Bristol-Myers Squibb Co. (U.S)
14.2.3. GlaxoSmithKline plc (GSK) (UK)
14.2.4. Merck & Co. Inc. (U.S)
14.2.5. Mylan Inc. (U.S)
14.2.6. Novartis AG (Switzerland)
14.2.7. Pfizer Inc. (U.S)
14.2.8. Sanofi (France)
14.2.9. Valeant Pharmaceuticals International Inc. (Canada)
15. Research Methodology
16. Key Assumptions and Acronyms

A complementary 2hrs free facility through which report buyers can interact with our pool of experienced analysts for any report related queries, clarifications or additional data requirements

OR

CALL US ON : 123456789

Request Customisation

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX